Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Medincell

Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth
From Medincell
Via Business Wire
Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark
From Medincell
Via Business Wire
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
From Medincell
Via Business Wire
Medincell to Join the Euronext SBF 120 Index
From Medincell
Via Business Wire
Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement
From Medincell
Via Business Wire
Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3
From Medincell
Via Business Wire
Medincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241
From Medincell
Via Business Wire
Medincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®
From Medincell
Via Business Wire
Medincell’s Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia
From Medincell
Via Business Wire
Medincell’s Partner Teva Provides New Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI)
From Medincell
Via Business Wire
Medincell Announces Progress in the Development of its Products Portfolio and R&D Pipeline
From Medincell
Via Business Wire
Medincell’s partner Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® commercial progress
From Medincell
Via Business Wire
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies
From Medincell
Via Business Wire
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
From Medincell
Via Business Wire
MedinCell’s Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI)
From MedinCell
Via Business Wire
MedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI)
From MedinCell
Via Business Wire
MedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749)
From MedinCell
Via Business Wire
US Biopharma Financial & IR Strategy Veteran Dr Grace Kim joins MedinCell
From MedinCell
Via Business Wire
MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total Knee Replacement
From MedinCell
Via Business Wire
MedinCell’s Partner Teva Announces Successful Launch of UZEDY™
From MedinCell
Via Business Wire
MedinCell: mdc-TJK's (Teva's codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)
From MedinCell
Via Business Wire
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
From MedinCell
Via Business Wire
MedinCell receives “Prime” ISS ESG rating as a recognition of the embedment of Corporate Social Responsibility across the Company
From MedinCell
Via Business Wire
Initiation of the Phase 3 study for the second long-acting injectable antipsychotic using MedinCell’s technology (program mdc-TJK)
From MedinCell
Via Business Wire
MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population
From MedinCell
Via Business Wire
Additional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive
From MedinCell
Via Business Wire
France : EIB and MedinCell Sign a New €40 Million Loan Agreement to Support Development of Innovative Treatments
From MedinCell
Via Business Wire
MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
From MedinCell
Via Business Wire
MedinCell’s Partner Teva Today Announced Refiling for Approval of mdc-IRM and Confirmed Planned Launch in the U.S. in H1 2023
From MedinCell
Via Business Wire
MedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of Its Global Health Mission
From MedinCell
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.